- Around 40% of available marketed drugs are poorly bioavailable or soluble, and about 90% of New Chemical Entities are known for their low solubility and permeability
- Lexaria’s patented DehydraTECH(TM) technology offers a solution by improving how APIs (active pharmaceutical ingredients) enter the bloodstream
- DehydraTECH achieves this by bypassing first-pass-liver metabolism
- By doing so, Lexaria is facilitating faster and much more thorough drug delivery
In a report published in the Bioavailability Enhancement Technologies and Services Market, 2018-2030, it was established that around 40% of available marketed drugs are poorly bioavailable or soluble. It was further estimated that approximately 90% of New Chemical Entities (“NCEs”) belong to Biopharmaceutics Classification System (“BCS”) class II and IV, known for their low solubility and permeability (https://ibn.fm/xfrBh).
Today, a significant number of drugs fail to reach the market owing to their poor bioavailability. This has prompted companies to re-formulate existing product candidates and explore different tools and methods to try to solve the problem.
Lexaria Bioscience (NASDAQ: LEXX) has taken on the challenge and is currently leading the industry in terms of innovation in drug delivery platforms. Its patented DehydraTECH(TM) technology is specifically designed to improve how active pharmaceutical ingredients (“APIs”) enter the bloodstream, ultimately increasing the effectiveness of fat-soluble molecules.
Lexaria’s DehydraTECH is a product of years of research and millions of dollars in investments. So far, the technology is covered by 23 issued and over 50 pending patents in 40 different countries worldwide.
The demand for solutions is so acute, that more and more companies are offering technologies and/or services geared towards bioavailability enhancement. In addition, several players have even developed novel, industry-leading technologies to maintain a competitive edge in this market that is showing great potential for growth. Lexaria recognized this opportunity back in 2014 and has been investing aggressively into research and the strategic partnerships it has forged so far.
Bioavailability can be described as how much an APIcan access the bloodstream within the body. This is typically dependent on absorption as well as secretion. It works on the principle that an API can only offer benefits if it can be absorbed into the body in the first place (https://ibn.fm/8DNGH).
One way through which drugs, particularly orally administered ones, have their bioavailability compromised is through first-pass liver processing. Usually, once they are ingested, they must travel from the intestine to the liver for metabolization, before they are circulated within the body and eventually to their targeted area. This arduous process can reduce the amount of drug that actually reaches the bloodstream by as much as twenty-fold inhibiting the effectiveness of the drug itself.
Because DehydraTECH bypasses this first-pass liver processing, the drugs begin to reach the bloodstream in as little as two minutes and often reach blood concentration levels between 100% and 200% higher. In addition, given the effectiveness of this technology, patients can also enjoy reduced drug dosing which has the potential to significantly lower the cost of treatment.
Lexaria remains committed to exploring new ways through which its DehydraTECH technology can help even more people. So far, it is investigating new products for hypertension, anti-viral treatments, oral nicotine, and other drug classes, with notable progress made so far. The company is also conducting research and development on several critical indications, including epilepsy, dementia, rheumatoid disease, diabetes, human hormones, Ibuprofen and Naproxen (“NSAIDs”), and PDE5 inhibitors.
Lexaria understands the value and usefulness of its technology, hence its commitment to further research and partnering with other strategic players within the industry. Its efforts improve the bioavailability of pharmaceuticals and therapeutics, one drug class at a time.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX.
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com